SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

01 Dec 2020 Evaluate

Glenmark Pharmaceuticals has informed that it has attached media release on 1st December 2020 titled ‘Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets, 1 mg and 5 mg’ which is self explanatory.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma Share Price

2241.30 -6.60 (-0.29%)
20-Apr-2026 12:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.90
Dr. Reddys Lab 1238.60
Cipla 1239.40
Zydus Lifesciences 940.70
Lupin 2331.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×